
    
      STUDY DESIGN AND ENROLLMENT Open label single arm pilot study enrolling Hispanic patients
      with HCV genotype 1 and naive to pegylated interferon and BOC treatment.

      Definition of BOC RGT:

      All patients will receive 4 weeks of PR (lead-in), and BOC will be added at the beginning of
      week 5. Patients who have an undetectable HCV RNA at week 8 and week 24 will receive 24 weeks
      of PR and BOC (28 weeks total treatment); patients who have a detectable HCV RNA at week 8,
      but an undetectable HCV RNA at week 24, will receive an additional 32 weeks of PR and BOC,
      followed by 12 weeks of PR (48 weeks total treatment).

      Patients with cirrhosis or bridging fibrosis (Stage 4 fibrosis) will receive 4 weeks of lead
      in followed by 44 weeks of BOC and PR (total 48 weeks).
    
  